BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3708
- Registration Number
- NCT04979780
- Locations
- 🇺🇸
Many Locations, Multiple Locations, Connecticut, United States
NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 100
- Registration Number
- NCT04945330
- Locations
- 🇯🇵
Many locations, Multiple Locations, Japan
A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 600
- Registration Number
- NCT04925180
- Locations
- 🇪🇸
Many Locations, Multiple Locations, Spain
A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 2627
- Registration Number
- NCT04923139
- Locations
- 🇯🇵
Japan databases, Japan Databases, Japan
🇯🇵Many Locations, Multiple Locations, Japan
RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins.
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 242
- Registration Number
- NCT04920422
- Locations
- 🇪🇸
Many Locations, Multiple Locations, Spain
A Study Called NATION-OS to Learn About the Link Between N-terminal proBNP (NT-proBNP) Levels and Medical Problems Due to Heart Failure (HF) in German Patients With HF
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 169
- Registration Number
- NCT04915118
- Locations
- 🇩🇪
Many locations, Multiple Locations, Germany
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 33
- Registration Number
- NCT04908436
A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 33
- Registration Number
- NCT04903821
- Locations
- 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
🇩🇪APEX GmbH, München, Bayern, Germany
A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate/Dienogest
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 255
- Registration Number
- NCT04901377
- Locations
- 🇷🇺
Many locations, Multiple Locations, Russian Federation
A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1500
- Registration Number
- NCT04899661
- Locations
- 🇯🇵
Many facilities, Multiple Locations, Japan
© Copyright 2024. All Rights Reserved by MedPath